Aeterna Zentaris Inc. (TSE:AEZS) has released an update.
Aeterna Zentaris Inc., a specialty biopharmaceutical firm, announced the completion of patient enrollment for its DETECT-trial evaluating macimorelin for diagnosing Childhood Onset Growth Hormone Deficiency. The company also reported a strong financial position with $34.0 million in cash, expected to support operations well into 2025, and a planned all-stock merger with Ceapro Inc. set to close in the second quarter of 2024. For the year 2023, Aeterna saw a reduction in net loss compared to the previous year and is optimistic about the future post-merger and trial results.
For further insights into TSE:AEZS stock, check out TipRanks’ Stock Analysis page.
